Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $138,475.08 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Kyle Jenne sold 1,823 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $75.96, for a total transaction of $138,475.08. Following the completion of the transaction, the executive vice president directly owned 16,389 shares of the company’s stock, valued at $1,244,908.44. The trade was a 10.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ionis Pharmaceuticals Stock Performance

Shares of NASDAQ IONS traded up $1.20 during midday trading on Tuesday, reaching $77.53. The company had a trading volume of 4,894,343 shares, compared to its average volume of 1,492,706. Ionis Pharmaceuticals, Inc. has a 1 year low of $23.95 and a 1 year high of $86.15. The business’s 50-day simple moving average is $78.90 and its 200 day simple moving average is $64.33. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock has a market cap of $12.56 billion, a P/E ratio of -45.88 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. The company had revenue of $156.72 million during the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.95) EPS. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IONS. Steigerwald Gordon & Koch Inc. purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $25,000. Golden State Wealth Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 198.4% during the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after purchasing an additional 250 shares during the last quarter. Mather Group LLC. acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $27,000. Allworth Financial LP grew its holdings in Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after buying an additional 517 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth $38,000. 93.86% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on IONS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada upped their price target on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Wells Fargo & Company lifted their price objective on Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Leerink Partners upped their target price on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Piper Sandler lifted their price target on Ionis Pharmaceuticals from $70.00 to $77.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.05.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.